MARKHAM, ON, Oct. 30 /CNW/ - Cytochroma today announced the appointment
of Ulrik Spork to its Board of Directors. Mr. Spork will represent Novo A/S on
the Company's Board and replaces Dr. Soren Schifter, who is leaving Novo A/S.
The number of Board members remains unchanged at six members.
"We are very pleased to welcome Ulrik Spork to our board and look forward
to drawing on his expertise and experiences as we continue building Cytochroma
into a leading CKD-focused specialty pharmaceutical company," stated Alan
Lewis, Ph.D., Chairman of Cytochroma's Board of Directors. "We would also like
to thank Soren Schifter for his advice to Cytochroma over the years, and wish
him well in the future."
Ulrik Spork has significant experience in corporate strategy, business
development, M&A, product development, and international marketing. As Senior
Partner, he led the establishment of venture investment activities by Novo A/S
from its inception in 1999. Prior to the formation of Novo A/S, Mr. Spork was
Director of Corporate Development at Novo Nordisk A/S, during which he was
involved in that company's strategic planning and managed a number of
acquisitions. He holds an MSc in Engineering from the Technical University of
Copenhagen and a BSc in International Economics.
Cytochroma is a clinical stage specialty pharmaceutical company focused
on developing and commercializing proprietary products to treat and prevent
the clinical consequences of vitamin D insufficiency and secondary
hyperparathyroidism associated with chronic kidney disease (CKD). The
Company's vitamin D-based therapeutics are designed to safely and effectively
treat patients with Stage 3, 4 or 5 CKD. In addition, Cytochroma is developing
novel therapies to treat hyperphosphatemia in these same patients. For more
information, please visit www.cytochroma.com.
For further information:
For further information: Gordon Ngan, Executive Director, Corporate
Development, Tel: (905) 479-5306 ext. 333, firstname.lastname@example.org; Media
Inquiries: Robert Stanislaro (FD), Tel: (212) 850-5657,